AIM ImmunoTech Inc. (AIM) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AIM Revenue Growth
Revenue Breakdown (FY 2022)
AIM's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
AIM Revenue Analysis (2013–2024)
As of May 8, 2026, AIM ImmunoTech Inc. (AIM) generated trailing twelve-month (TTM) revenue of $112,000, reflecting significant decline in growth of -25.7% year-over-year. The most recent quarter (Q3 2025) recorded $26,000 in revenue, up 4.0% sequentially.
Looking at the longer-term picture, AIM's 5-year compound annual growth rate (CAGR) stands at +4.0%, indicating moderate growth over time. The company achieved its highest annual revenue of $437,000 in 2017.
Revenue diversification analysis shows AIM's business is primarily driven by Clinical Treatment Programs - US (100%). With over half of revenue concentrated in Clinical Treatment Programs - US, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IMMP (+54.3% YoY), NKTR (-43.9% YoY), and IOVA (+34.3% YoY), AIM has underperformed the peer group in terms of revenue growth. Compare AIM vs IMMP →
AIM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AIMCurrent | $112,000 | -25.7% | +4.0% | -11630.6% | |
 IMMP | $5M | +54.3% | -7.6% | -2506.5% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% |
AIM Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $170K | -15.8% | $139K | 81.8% | $-19,772,000 | -11630.6% |
| 2023 | $202K | +43.3% | $160K | 79.2% | $-31,916,000 | -15800.0% |
| 2022 | $141K | +4.4% | $565K | 400.7% | $-19,922,810 | -14129.7% |
| 2021 | $135K | -17.2% | $-715,000 | -529.6% | $-18,838,000 | -13954.1% |
| 2020 | $163K | +16.4% | $-643,000 | -394.5% | $-15,152,000 | -9295.7% |
| 2019 | $140K | -61.9% | $-753,000 | -537.9% | $-12,443,000 | -8887.9% |
| 2018 | $367K | -16.0% | $-517,000 | -140.9% | $-11,496,000 | -3132.4% |
| 2017 | $437K | +375.0% | $-746,000 | -170.7% | $-11,416,000 | -2612.4% |
| 2016 | $92K | -30.8% | $-1,016,000 | -1104.3% | $-13,804,000 | -15004.3% |
| 2015 | $133K | -32.5% | $-1,465,000 | -1101.5% | $-16,650,000 | -12518.8% |
See AIM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AIM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AIM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAIM — Frequently Asked Questions
Quick answers to the most common questions about buying AIM stock.
Is AIM's revenue growth accelerating or slowing?
AIM revenue declined -25.7% year-over-year, contrasting with the 5-year CAGR of +4.0%. TTM revenue fell to $112000.00. This reverses the prior growth trend.
What is AIM's long-term revenue growth rate?
AIM ImmunoTech Inc.'s 5-year revenue CAGR of +4.0% reflects the variable expansion pattern. Current YoY growth of -25.7% is below this long-term average.
How is AIM's revenue distributed by segment?
AIM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.